By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Regeneron Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-847-7000 Fax: n/a


SEARCH JOBS



Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.

Visit our website – www.regeneron.com
Check out our openings – www.careers.regeneron


Key Statistics


Email:
Ownership: Public

Web Site: Regeneron
Employees: 2300+
Symbol: REGN
 



Industry
Biotechnology


Collaborations

Sanofi US 

Bayer Corporation 

Geisinger Health System  Collaboration with Regeneron Genetics Center LLC, wholly-owned subsidiary of Regeneron.

Avalanche Biotechnologies 





Company News
Regeneron (REGN)-Sanofi (SAN.PA) Gain Edge On Amgen (AMGN) as Cholesterol Drug Snags FDA Priority Review 1/26/2015 6:26:26 AM
Regeneron (REGN) And Sanofi (SAN.PA) Announce Praluent™ (Alirocumab) Biologics License Application Has Been Accepted For Priority Review By FDA 1/26/2015 6:24:59 AM
Regeneron (REGN) Release: EYLEA® (aflibercept) Injection Recommended For Approval For The Treatment Of Visual Impairment Due To Macular Edema Secondary To Central Or Branch Retinal Vein Occlusion In The European Union 1/23/2015 10:14:20 AM
Targets Of Next Express Scripts Inc. Price War: Amgen (AMGN) and Regeneron (REGN) 1/14/2015 6:06:42 AM
Regeneron (REGN) And Sanofi (SAN.PA) Announce Praluent™ (alirocumab) Marketing Authorization Application Has Been Accepted For Review By European Medicines Agency 1/12/2015 7:09:00 AM
Regeneron (REGN) To Report Fourth Quarter And Full Year 2014 Financial And Operating Results And Host Conference Call And Webcast On February 10, 2015 1/9/2015 8:42:18 AM
Regeneron (REGN) And Sanofi (SAN.PA) Announce Positive Topline Results From First Phase 3 Trials Evaluating Monthly Dosing Of Alirocumab In Patients With Hypercholesterolemia 1/9/2015 6:02:35 AM
Regeneron (REGN), Sanofi (SAN.PA) Show Off Positive Cholesterol Drug Data 1/9/2015 6:01:19 AM
Regeneron (REGN)'s Schleifer Amongst The Best Compensated CEOs In New York 12/24/2014 8:37:29 AM
Regeneron (REGN), Sanofi (SAN.PA) Test The Public's Cholesterol IQ To Prep For Alirocumab Launch 12/16/2014 6:05:01 AM
12345678910...
//-->